The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental.

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Cathie Wood’s trades often read like a quiet manifesto – what she buys signals confidence, what she trims hints at fading faith. In the week ended Dec. 19, that message was clear. ARK Investment ...

Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

The surge of AI has, for an array of users, complicated tasks such as fixing a blocked bank account, reporting fraud or ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. David Kindness is a Certified Public ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician ...

Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...